Dialogues

Jan 22, 2025, 07:31

ASCO24 Updates: Juneko Grilley-Olson on Advancing Angiosarcoma Treatment

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Juneko Grilley-Olson, medical oncologist at Duke University, shared insights on ‘Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).‘

My name is Juneko Grilley-Olson. I’m a medical oncologist at Duke University in Durham, North Carolina. And at ASCO this year, we presented the Alliance Study A091401 of angiosarcoma in patients that are taxa-naive.

So in this study, patients with advanced angiosarcoma who have limited treatment options were randomized to receive either paclitaxel with or without nivolumab. In the study, the portions that we presented last year were of patients with taxane pretreated angiosarcomas with cabizantinib nivolumab. In this portion, patients could not have received any checkpoint inhibitors or prior VEGF-TKIs.

The primary outcome of the study was progression-free survival of the combination versus the paclitaxel monotherapy.

The primary outcome was not met in this portion of the study with paclitaxel plus nivolumab not demonstrating an improvement in progression-free survival over paclitaxel alone. However, when we looked at the subset analysis, which was not powered for statistical significance, the patients with angiosarcoma of the scalp and face did trend toward an improvement in overall survival with a doubling of the progression-free survival from eight months with paclitaxel monotherapy to 16 months with a combination of paclitaxel plus nivolumab.

So again, this was not powered to detect a significant difference with it, but it certainly is intriguing in that particular population. In the overall survival population, there was no different seen either with perhaps a trend toward benefit with paclitaxel monotherapy, although importantly, the paclitaxel arm outperformed historic controls. In the next steps, we’re looking toward developing a trial to really establish a first-line standard of care therapy in angiosarcomas.

More videos and content from ASCO 2024 on OncoDaily.